235 research outputs found
c-Myc deregulation is involved in melphalan resistance of Multiple Myeloma: role of PDGF-BB
No full textTra Età del bronzo e Età del ferro in Corsica e in Sardegna: riflessioni alla luce delle nuove indagini condotte a Puzzonu (Quenza, Corse-du-Sud), in Materiali per Populonia 11
No full textRicerche archeologiche in Corsica e Sardegn
Tra Età del bronzo e Età del ferro in Corsica e in Sardegna: riflessioni alla luce delle nuove indagini condotte a Puzzonu (Quenza, Corse-du-Sud)
No full textProspective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
No full textAlessandra Fabi,1 Diana Giannarelli,2 Paola Malaguti,1 Gianluigi Ferretti,1 Sabrina Vari,1 Paola Papaldo,1 Cecilia Nisticò,1 Mauro Caterino,3 Roy De Vita,4 Marcella Mottolese,5 Laura Iacorossi,6 Francesco Cognetti1 1Department of Medical Oncology, 2Biostatistic Unit, 3Service of Radiology, 4Operative Unit of Plastic and Reconstructive Surgery, Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy; 5Department of Pathology, 6Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy Background: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, since even today it remains an incurable disease. Taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined schedules, but the need for synthetic solvents contributes to the severe toxicities and may have a negative impact on the efficacy. Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) is a colloidal suspension of paclitaxel and human serum albumin initially developed to avoid the toxicities associated with conventional taxanes.Patients and methods: The aim of this prospective, single-center open-label, noncomparative study was to evaluate the efficacy and safety of nab-paclitaxel in MBC patients pretreated with taxanes. The patients were treated with nab-paclitaxel as a single agent, 260 mg/m2 on day 1 of each 3-week cycle or 125 mg/m2 weekly. The primary endpoint was the overall response rate (ORR). Secondary objectives were duration of response, clinical benefit rate, progression-free survival (PFS), overall survival, and safety.Results: A total of 42 patients (median age 48 years, median Eastern Cooperative Oncology Group performance status 0, triple-negative MBC 19%, all pretreated with a taxane-based therapy, mainly in advanced disease) were enrolled in the study. The ORR was 23.8%, including one complete response (2.4%) and nine partial responses (21.4%); the disease control rate was 50%. The median duration of response was 7.2 months. After a median follow-up of 9 months, the median PFS was 4.6 months. ORR and PFS were similar irrespective of the previous chemotherapy lines, metastatic sites, and biomolecular expression. Nab-paclitaxel was well tolerated, and the most frequent treatment-related toxicities were mild to moderate (grades 1–2).Conclusion: This real-life study shows that nab-paclitaxel has a significant antitumor activity and a manageable safety profile in patients pretreated with taxanes and experiencing a treatment failure after at least one line of chemotherapy. Keywords: nab-paclitaxel, metastatic breast cancer, anthracycline
C-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: Clinical and experimental findings
No full textThe aim of this study was twofold: to assess the rela-tionship between c-Myb and Bcl-x expression and toevaluate the prognostic significance of their expres-sion in colorectal carcinoma (CRC) patients. Analysisof tumors from 91 CRC patients for expression ofc-Myb and Bcl-x revealed a significant relationshipbetween these two proteins. Kaplan-Meier’s analysisshowed an increased risk of relapse and death inpatients whose tumor specimens displayed highc-Myb levels and Bcl-x positivity. Similar results werealso observed excluding Dukes’ D patients. Molecularanalysis using three c-Myb-overexpressing LoVoclones indicated that c-Myb overexpression was ac-companied by up-regulation of Bcl-xL protein andmRNA. Tumors originating from these clones injectedin nude mice were significantly larger than thoseformed in mice injected with parental or vector-trans-fected LoVo cells. Moreover , tumors derived from pa-rental and control vector-transfected but not fromc-Myb-overexpressing LoVo cells showed high fre-quency of apoptotic cells. These results provide directevidence of an association between c-Myb and Bcl-xexpression and suggest that expression of both mol-ecules might be a useful prognostic marker in CRC
Autistic-relevant behavioral phenotypes of a mouse model of cyclin-dependent kinase-like 5 deficiency disorder
No full textCyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a neurodevelopmental disease caused by mutations in the X-linked CDKL5 gene and characterized by early-onset epilepsy, intellectual disability, and autistic features. To date, the etiological mechanisms underlying CDD are largely unknown and no effective therapies are available. The Cdkl5 knock-out (KO) mouse has been broadly employed in preclinical studies on CDD; Cdkl5-KO mice display neurobehavioral abnormalities recapitulating most CDD symptoms, including alterations in motor, sensory, cognitive, and social abilities. However, most available preclinical studies have been carried out on adult Cdkl5-KO mice, so little is known about the phenotypic characteristics of this model earlier during development. Furthermore, major autistic-relevant phenotypes, for example, social and communication deficits, have been poorly investigated and mostly in male mutants. Here, we assessed the autistic-relevant behavioral phenotypes of Cdkl5-KO mice during the first three post-natal weeks and in adulthood. Males and females were tested, the latter including both heterozygous and homozygous mutants. Cdkl5 mutant pups showed qualitative and quantitative alterations in ultrasonic communication, detected first at 2 weeks of age and confirmed later in adulthood. Increased levels of anxiety-like behaviors were observed in mutants at 3 weeks and in adulthood, when stereotypies, reduced social interaction and memory deficits were also observed. These behavioral effects of the mutation were evident in both sexes, being more marked and varied in homozygous than heterozygous females. These findings provide novel evidence for the autistic-relevant behavioral profile of the Cdkl5 mouse model, thus supporting its use in future preclinical studies investigating CDD pathology and autism spectrum disorders
Cardiovascular risk factors and coronary damage in patients with ischemic brain disease.
No full textBrachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis
No full text: We present a patient with a large B cell gastric lymphoma in total remission who, after 4 months, developed a fatal progressive peripheral neuropathy with an unusual early involvement of the right brachial plexus. No evidence of lymphoma was found at whole body computed tomography, magnetic resonance imaging of the head, cervical spine and right brachial plexus, bone marrow biopsy or repeated lumbar punctures. The diagnosis of neurolymphomatosis was made only at postmortem examination
Sincope ricorrente: attenti alla coronaria
No full textDopo l’Aggiornamento pubblicato sul numero di aprile sulle sincopi, torniamo a parlarne, a partire da un caso clinico, con un approfondimento su una delle cause più temibili da causa cardiaca: l’anomalia di origine delle coronarie. Si riportano gli indici di sospetto (quando pensarci) e i criteri per la diagnosi, non sempre facile. Con uno sguardo rivolto anche alle altre possibili cause di sincope da causa cardiaca (vedi anche Il commento a seguire)
- …
